, Volume 12, Issue 2, pp 298–304 | Cite as

Euthyroid Graves’ orbitopathy and incidental papillary thyroid microcarcinoma

  • Eugen Melcescu
  • William B. Horton
  • Karen T. Pitman
  • Vani Vijayakumar
  • Christian A. KochEmail author
Case report


Euthyroid Graves’ orbitopathy (GO) combined with incidental papillary thyroid microcarcinoma has rarely been reported. CASE REPORT: A 61-year-old caucasian woman initially presented with progressive fatigue, exophthalmos, and thyroid function tests within normal limits. She underwent thyroidectomy, was found to have two incidental papillary thyroid microcarcinomas, and received radioactive iodine ablation to eliminate thyroid antigen. In addition to following her eye disease, TSH-receptor antibodies, thyroid stimulating immunoglobulins, and serum thyroglobulin measurements were recorded, demonstrating no evidence of thyroid cancer at four-year follow-up. At first, she had mild GO, developing into moderate-to-severe GO, and at 4 years she had Hertel measurements of 20 mm in both eyes. CONCLUSION: This report underscores the difficulty of managing GO even when thyroid function is normal(ized) and thyroid antigen exposure has been minimized. In addition, it illustrates why antithyroidal antibodies should be considered in cases of concomitant papillary thyroid cancer, as thyroid cells can be stimulated not only by TSH but also by TSH-receptor stimulating antibodies.

Key words

Antibody Graves’ disease Orbitopathy Radioactive iodine Thyroid carcinoma 


  1. 1.
    Melcescu E, Horton WB, Kim D, et al, 2013 Graves’ orbitopathy: update on diagnosis and therapy. South Med J: in press.Google Scholar
  2. 2.
    Khoo DH, Eng PH, Ho SC, et al, 2000 Graves’ ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels. Thyroid 10: 1093–1100.CrossRefGoogle Scholar
  3. 3.
    Marcocci C, Bartalena L, Bogazzi F, et al, 1989 Studies on the occurrence of ophthalmopathy in Graves’ disease. Acta Endocrinol 120: 473–478.CrossRefGoogle Scholar
  4. 4.
    Paunkovic J, Paunkovic N, 2006 Does autoantibody-negative Graves’ disease exist? A second evaluation of the clinical diagnosis Horm Metab Res 38: 53–56.CrossRefGoogle Scholar
  5. 5.
    Bartalena L, Tanda ML, 2009 Clinical practice. Graves’ ophthalmopathy. New Engl J Med 360: 994–1001.CrossRefGoogle Scholar
  6. 6.
    Pfeilschifter J, Ziegler R, 1996 Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption. Clin Endocrinol (Oxf) 45: 477–481.CrossRefGoogle Scholar
  7. 7.
    Bahn RS, 2000 Understanding the immunology of Graves’ ophthalmopathy. Is it an autoimmune disease? Endocrinol Metab Clin North Am 29: 287–296.CrossRefGoogle Scholar
  8. 8.
    Bahn RS, 2010 Graves’ ophthalmopathy. New Engl J Med 362: 726–738.CrossRefGoogle Scholar
  9. 9.
    Lytton SD, Ponto KA, Kanitz M, et al, 2010 A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves’ orbitopathy. J Clin Endocrinol Metab 95: 2123–2131.CrossRefGoogle Scholar
  10. 10.
    Dragan LR, Seiff SR, Lee DC, 2006 Longitudinal correlation of thyroid-stimulating immunoglobulin with clinical activity of disease in thyroid-associated orbitopathy. Ophthal Plast Reconstr Surg 22: 13–19.CrossRefGoogle Scholar
  11. 11.
    Duh QY, 2004 Thyroid cancer in Graves disease: incidental cancer versus clinical cancer. Ann Surg Oncol 11: 356–357.CrossRefGoogle Scholar
  12. 12.
    Biscolla RP, Ugohm C, Sculli M, et al, 2004 Medullary and papillary tumors are frequently associated in the same thyroid gland without evidence of reciprocal influence in their biologic behavior. Thyroid 14: 946–952.CrossRefGoogle Scholar
  13. 13.
    Carlini M, Giovannini C, Castaldi F et al, 2005 High risk for microcarcinoma in thyroid benign diseases. Incidence in a one year period of total thyroidectomies. J Exp Clin Cancer Res 24: 231–236.PubMedGoogle Scholar
  14. 14.
    Dietlein M, Luyken WA, Schicha H, Larena-Avellaneda A, 2005 Incidental multifocal papillary microcarcinomas of the thyroid: is subtotal thyroidectomy combined with radioiodine ablation enough? Nucl Med Commun 26: 3–8.CrossRefGoogle Scholar
  15. 15.
    Kovács GL, Gonda G, Vadász G, et al, 2005 Epidemiology of thyroid microcarcinoma found in autopsy series conducted in areas of different iodine intake. Thyroid 15: 152–157.CrossRefGoogle Scholar
  16. 16.
    Neuhold N, Kaiser H, Kaserer K, 2001 Latent carcinoma of the thyroid in Austria: a systematic autopsy study. Endocr Pathol 12: 23–31.CrossRefGoogle Scholar
  17. 17.
    Harach HR, Franssila KO, Wasenius VM, 1985 Occult papillary carcinoma of the thyroid. A “normal” finding in Finland. A systemic autopsy study. Cancer 56: 531–538.CrossRefGoogle Scholar
  18. 18.
    Furlan JC, Rosen IB, 2004 Prognostic relevance of previous exposure to ionizing radiation in well-differentiated thyroid cancer. Langenbecks Arch Surg 389: 198–203.CrossRefGoogle Scholar
  19. 19.
    Belfiore A, Garofalo MB, Giuffrida D, et al, 1990 Increased aggressiveness of thyroid cancer in patients with Graves’ disease. J Clin Endocrinol Metab 70: 830–835.CrossRefGoogle Scholar
  20. 20.
    Ozaki O, Ito K, Kobayashi K, et al, 1990 Thyroid carcinoma in Graves’ disease. World J Surg 14: 437–440.CrossRefGoogle Scholar
  21. 21.
    Mazzaferri EL, 1990 Thyroid cancer and Graves’ disease. J Clin Endocrinol Metab 70: 826–829.CrossRefGoogle Scholar
  22. 22.
    Pellegriti G, Belfiore A, Giuffrida D, et al, 1998 Outcome of differentiated thyroid cancer in Graves’ patients. J Clin Endocrinol Metab 83: 2805–2809.PubMedGoogle Scholar
  23. 23.
    Feldt-Rasmussen U, Rasmussen AK, 2010 Autoimmunity in differentiated thyroid cancer: significance and related clinical problems. Hormones (Athens) 9:109–117.CrossRefGoogle Scholar
  24. 24.
    Melcescu E, Hogan RB 2nd, Brown K, et al, 2012 The various faces of autoimmune endocrinopathies: Non-tumoral hypergastrinemia in a patient with lymphocytic colitis and chronic autoimmune gastritis. Exp Mol Pathol 93: 434–440.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Melcescu E, Kemp EH, Majithia V, et al, 2013 Graves’ disease, hypoparathyroidism, systemic lupus erythematosus, alopecia, and angioedema: autoimmune polyglandular syndrome variant or coincidence? Int J Immunopathol Pharmacol 26: 237–242.CrossRefGoogle Scholar
  26. 26.
    Nart A, Uslu A, Aykas A, et al, 2008 Total thyroidectomy for the treatment of recurrent Graves’ disease with ophthalmopathy. Asian J Surg 31: 115–118.CrossRefGoogle Scholar
  27. 27.
    Hautzel H, Pisar E, Yazdan-Doust N, et al, 2010 Qualitative and quantitative impact of protective glucorticoid therapy on the effective 131I half-life in radioiodine therapy for Graves’ disease. J Nucl Med 51: 1917–1922.CrossRefGoogle Scholar
  28. 28.
    Kahaly GJ, Pitz S, Hommel G, Dittmar M, 2005 Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J Clin Endocrinol Metab 90: 5234–5240.CrossRefGoogle Scholar
  29. 29.
    Guarneri F, Benvenga S, 2007 Environmental factors and genetic background that interact to cause autoimmune thyroid disease. Curr Opin Enocrinol Diabetes Obes 14: 398–409.CrossRefGoogle Scholar
  30. 30.
    Vita R, Lapa D, Trimarchi F, et al, 2009 A patient with stress-related onset and exacerbations of Graves disease. Nat Clin Pract Endocrinol Metab 5: 55–61.CrossRefGoogle Scholar
  31. 31.
    Pantalone KM, Nasr C, 2010 Approach to a low TSH level: patience is a virtue. Cleve Clin J Med 77: 803–811.CrossRefGoogle Scholar
  32. 32.
    Antonelli A, Fallahi P, Tolari S, et al, 2008 Thyroid-associated ophthalmopathy and TSH receptor autoantibodies in nonmetastatic thyroid cancer after total thyroidectomy. Am J Med Sci 336: 288–290.CrossRefGoogle Scholar
  33. 33.
    Schott M, Minich WB, Willenberg HS, et al, 2005 Relevance of TSH receptor stimulating and blocking autoantibody measurement for the prediction of relapse in Graves’ disease. Horm Metab Res 37: 741–744.CrossRefGoogle Scholar
  34. 34.
    Eckstein A, Esser J, Mann K, Schott M, 2010 Clinical value of TSH receptor antibodies measurement in patients with Graves’ orbitopathy. Pediatr Endocrinol Rev 7: Suppl 2: 198–203.PubMedGoogle Scholar
  35. 35.
    Lytton SD, Li Y, Olivo PD, et al, 2010 Novel chimeric thyroid-stimulating hormone-receptor bioassay for thyroid-stimulating immunoglobulins. Clin Exp Immunol 162: 438–446.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Sarlis NJ, Brucker-Davis F, Swift JP, et al, 1997 Graves’ disease following thyrotoxic painless thyroiditis. Analysis of antibody activities against the thyrotropin receptor in two cases. Thyroid 7: 829–836.CrossRefGoogle Scholar
  37. 37.
    McLachlan SM, Rapoport B, 2013 Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa. Thyroid 23: 14–24.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Martinez O, Gangi E, Mordi D, et al, 2007 Diversity in the complementarity-determining region 3 (CDR3) of antibodies from mice with evolving anti-thyroid-stimulating hormone receptor antibody responses. Endocrinology 148: 752–761.CrossRefGoogle Scholar
  39. 39.
    Pazaitou-Panayiotou K, Michalakis K, Paschke R, 2012 Thyroid cancer in patients with hyperthyroidism. Horm Metab Res 44: 255–262.CrossRefGoogle Scholar
  40. 40.
    Collier A, Ghosh S, Hair M, et al, 2009 Comparison of two fixed activities of radioiodine therapy (370 vs. 555 MBq) in patients with Graves’ disease. Hormones (Athens) 8: 273–278.CrossRefGoogle Scholar
  41. 41.
    De Bellis A, Conzo G, Cennamo G, et al, 2012 Time course of Graves’ ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study. Endocrine 41: 320–326.CrossRefGoogle Scholar
  42. 42.
    Tamatea JA, Tu’akoi K, Conaglen JV, et al, 2012 Thyroid cancer in Graves’ disease: is surgery the best treatment for Graves’ disease? ANZ J Surg,
  43. 43.
    Durante C, Attard M, Torlontano M, et al, 2010 Identification and optimal postsurgical follow-up of patients with very low-risk papillary thyroid microcarcinomas. J Clin Endocrinol Metab 95: 4882–4888.CrossRefGoogle Scholar
  44. 44.
    Madaschi S, Rossini A, Formenti I, et al, 2010 Treatment of thyroid-associated orbitopathy with rituximab-a novel therapy for an old disease: case report and literature review. Endocr Pract 16: 677–685.CrossRefGoogle Scholar
  45. 45.
    Bartalena L, 2010 What to do for moderate-to-severe and active Graves’ orbitopathy if glucocorticoids fail? Clin Endocrinol (Oxf) 73: 149–152.Google Scholar
  46. 46.
    Antonelli A, Ferrari SM, Frascerra S, et al, 2012 Peroxisome proliferator-activated receptor-α agonists modulate CXCL9 and CXCL11 chemokines in Graves’ ophthalmopathy fibroblasts and preadipocytes. Mol Cell Endocinol 349: 255–261.CrossRefGoogle Scholar
  47. 47.
    Antonelli A, Ferrari SM, Frascerra S, et al, 2012 β (CCL2) and α (CXCL10) chemokine modulations by cytokines and peroxisome proliferator-activated receptor-α agonists in Graves’ ophthalmopathy. J Endocrinol 213: 183–191.CrossRefGoogle Scholar

Copyright information

© Hellenic Endocrine Society 2013

Authors and Affiliations

  • Eugen Melcescu
    • 1
  • William B. Horton
    • 1
  • Karen T. Pitman
    • 2
    • 3
  • Vani Vijayakumar
    • 3
    • 4
  • Christian A. Koch
    • 1
    • 3
    • 5
    Email author
  1. 1.Department of MedicineUniversity of Mississippi Medical CenterJacksonUSA
  2. 2.Department of OtolaryngologyUniversity of Mississippi Medical CenterJacksonUSA
  3. 3.Cancer Institute, Division of Endocrinology, University of Mississippi Medical CenterUniversity of Mississippi Medical CenterJacksonUSA
  4. 4.Department of Radiology / Nuclear MedicineUniversity of Mississippi Medical CenterJacksonUSA
  5. 5.G.V. (Sonny) Montgomery VA Medical CenterMedical ServiceJacksonUSA

Personalised recommendations